Highlights

Simons Trading Research

Author: simonsg   |   Latest post: Wed, 18 May 2022, 11:34 AM

 

Venture Corp - Steady Recovery

Author:   |    Publish date:


Recovery Continues; Maintain BUY

  • Venture Corp (SGX:V03)'s 2H20 PATMI of S$166.8m (-8.1% y-o-y) was in line with our estimate, and met the lower end of street’s.
  • We trim our Venture Corp's FY21-22E earnings per share forecasts by 4-5% to fine-tune margin assumptions, although our revenue numbers are largely unchanged – reflecting our confidence of the ongoing recovery. New products are on track for launch in 2Q21 and into 2H21.
  • Maintain BUY with lower target price of S$22.00 on unchanged 18.5x FY21E P/E (1.5 standard deviation above 4-year mean).

Resilient Revenue and Margins From Diversity

  • Venture Corp's 2H20 revenue fell 8.6% y-o-y to S$1.65b, although this was up 20.6% h-o-h. Several end-markets were affected by COVID-19, particularly those facing retail end-markets (e.g. POS, consumer electronics), but this was offset by resilience in life-science, networking and communication and semicon, which are beneficiaries in the pandemic.
  • As Venture Corp’s value-add is higher in the life-science domain, net margin was flat y-o-y at 10.1% despite lower volumes.

Leveraging R&D to Capture Opportunities

  • Growth in the life science domain is expected to be driven by genomics-related products and advanced equipment for analysis/ diagnostics in biological systems. COVID-19 also presents opportunities to develop pandemic-related testing and diagnostic products.
  • Venture Corp says it is leveraging its R&D capabilities to develop cutting-edge products in life science, medical devices and lifestyle and wellness consumer products.

Moving Into Interesting Domains

  • Venture Corp will widen its participation in robotics, automation and AI, and advanced semiconductor equipment domains.
  • Venture Corp is also optimistic in being able to capture value in adjacent domains, such as battery EVs, through its breadth of know-how across multiple domains.
  • We believe key risks are:
    1. outbreak of COVID-19 in Venture Corp’s plants, which may hinder production schedules;
    2. chip shortages within supply chains Venture Corp are exposed to; and
    3. slower-than-expected economic recovery.

Source: Maybank Kim Eng Research - 1 Mar 2021

Share this
Labels: Venture

Related Stocks

Chart Stock Name Last Change Volume 
Venture 17.25 -0.11 (0.63%) 494,400 

  Be the first to like this.
 


APPS
I3 Messenger
Individual or Group chat with anyone on I3investor
 
 

135  249  195  599 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 Sembcorp Marine 0.106+0.003 
 YZJ Fin Hldg 0.485+0.05 
 Jiutian Chemical 0.11-0.001 
 AA 0.014-0.003 
 HSI 21400MBeC.. 0.057-0.018 
 Parkson Retail 0.049+0.004 
 Dyna-Mac 0.149+0.002 
 HSI 18200MBeP.. 0.061+0.009 
 Tritech 0.036+0.001 
 Genting Sing 0.785-0.005 
PARTNERS & BROKERS